spermine has been researched along with Blood Poisoning in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the safety, tolerability, pharmacokinetics, and efficacy of kukoamine B (KB), an alkaloid compound with high affinity for both lipopolysaccharide (LPS) and oligodeoxynucle-otides containing CpG motifs (CpG DNA), in patients with sepsis-induced organ failure." | 9.69 | Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial. ( Chen, S; Dong, K; Du, B; Feng, Y; Hu, P; Hu, XY; Hu, Z; Jiang, W; Jin, C; Liu, H; Sun, Y; Wang, CY; Wang, D; Wang, H; Wang, T; Yao, X; Zang, B; Zhang, W; Zhao, Q; Zhou, J, 2023) |
| "To assess the appropriateness of the body weight or fixed dosing regimen, a population pharmacokinetic (PopPK) model of kukoamine B has been built in sepsis patients." | 9.51 | Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation. ( Chen, S; Deng, C; Dong, K; Du, B; Hu, P; Hu, X; Jiang, J; Jin, C; Qin, H; Wang, H; Wang, T; Zhao, Q, 2022) |
| " In this report, we developed microparticles based on polymerization of alpha-ketoglutarate (a Krebs cycle metabolite), with or without encapsulation of spermine (a polyamine metabolite), to modulate cell phenotype that are critical for resolution of inflammation." | 8.31 | Biomaterial mediated simultaneous delivery of spermine and alpha ketoglutarate modulate metabolism and innate immune cell phenotype in sepsis mouse models. ( Acharya, AP; de Ávila, C; Esrafili, A; Fryer, JD; Halim, M; Inamdar, S; Jaggarapu, MMCS; Lintecum, K; Mantri, S; Ng, ND; Schmitzer, E; Spiller, KL; Suresh, AP; Thumsi, A; Tylek, T; Xu, Y, 2023) |
| "To investigate the inhibitory effect of kukoamine B (KB) on lung inflammatory responses in mice with sepsis and its possible molecular mechanism." | 7.80 | [Inhibitory effect of kukoamine B on lung inflammatory responses in mice with sepsis]. ( Lyu, W; Qin, W; Shen, W; Sun, B; Wang, X; Zhang, J, 2014) |
| "To evaluate the safety, tolerability, pharmacokinetics, and efficacy of kukoamine B (KB), an alkaloid compound with high affinity for both lipopolysaccharide (LPS) and oligodeoxynucle-otides containing CpG motifs (CpG DNA), in patients with sepsis-induced organ failure." | 5.69 | Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial. ( Chen, S; Dong, K; Du, B; Feng, Y; Hu, P; Hu, XY; Hu, Z; Jiang, W; Jin, C; Liu, H; Sun, Y; Wang, CY; Wang, D; Wang, H; Wang, T; Yao, X; Zang, B; Zhang, W; Zhao, Q; Zhou, J, 2023) |
| "To assess the appropriateness of the body weight or fixed dosing regimen, a population pharmacokinetic (PopPK) model of kukoamine B has been built in sepsis patients." | 5.51 | Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation. ( Chen, S; Deng, C; Dong, K; Du, B; Hu, P; Hu, X; Jiang, J; Jin, C; Qin, H; Wang, H; Wang, T; Zhao, Q, 2022) |
| "It is thus a promising strategy to treat sepsis by discovering agents that neutralize LPS and CpG DNA simultaneously." | 5.37 | Dual targets guided screening and isolation of Kukoamine B as a novel natural anti-sepsis agent from traditional Chinese herb Cortex lycii. ( Cao, H; Liu, X; Long, Y; Lu, Y; Wang, N; Zhao, K; Zheng, J; Zheng, X; Zhou, H, 2011) |
| "The present drugs for treating sepsis act only against either LPS or CpG DNA." | 5.37 | Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment. ( Cao, H; Liu, X; Long, Y; Lu, Y; Wang, N; Zhao, K; Zheng, J; Zheng, X; Zhou, H, 2011) |
| " In this report, we developed microparticles based on polymerization of alpha-ketoglutarate (a Krebs cycle metabolite), with or without encapsulation of spermine (a polyamine metabolite), to modulate cell phenotype that are critical for resolution of inflammation." | 4.31 | Biomaterial mediated simultaneous delivery of spermine and alpha ketoglutarate modulate metabolism and innate immune cell phenotype in sepsis mouse models. ( Acharya, AP; de Ávila, C; Esrafili, A; Fryer, JD; Halim, M; Inamdar, S; Jaggarapu, MMCS; Lintecum, K; Mantri, S; Ng, ND; Schmitzer, E; Spiller, KL; Suresh, AP; Thumsi, A; Tylek, T; Xu, Y, 2023) |
| "To investigate the inhibitory effect of kukoamine B (KB) on lung inflammatory responses in mice with sepsis and its possible molecular mechanism." | 3.80 | [Inhibitory effect of kukoamine B on lung inflammatory responses in mice with sepsis]. ( Lyu, W; Qin, W; Shen, W; Sun, B; Wang, X; Zhang, J, 2014) |
| "It is thus a promising strategy to treat sepsis by discovering agents that neutralize LPS and CpG DNA simultaneously." | 1.37 | Dual targets guided screening and isolation of Kukoamine B as a novel natural anti-sepsis agent from traditional Chinese herb Cortex lycii. ( Cao, H; Liu, X; Long, Y; Lu, Y; Wang, N; Zhao, K; Zheng, J; Zheng, X; Zhou, H, 2011) |
| "The present drugs for treating sepsis act only against either LPS or CpG DNA." | 1.37 | Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment. ( Cao, H; Liu, X; Long, Y; Lu, Y; Wang, N; Zhao, K; Zheng, J; Zheng, X; Zhou, H, 2011) |
| "Sepsis, otherwise referred to as "blood poisoning" is a serious clinical problem, the incidence of which continues to rise in the US and worldwide despite advances in antimicrobial chemotherapy." | 1.36 | Development of small-molecule endotoxin sequestering agents. ( David, SA; Sil, D, 2010) |
| "1 cells, as well as TNF-alpha in human blood, is inhibited in a dose-dependent manner by 4e at concentrations orders of magnitude lower than toxic doses." | 1.33 | Lipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomospermines. ( Cromer, JR; Datta, A; David, SA; Miller, KA; Suresh Kumar, EV; Wood, SJ, 2005) |
| "Sepsis was induced by cecal ligation and puncture (CLP); control rats were sham-operated." | 1.29 | Influence of sepsis and endotoxemia on polyamine metabolism in mucosa of small intestine in rats. ( Fischer, JE; Hasselgren, PO; Meyer, TA; Noguchi, Y; Ogle, CK; Tiao, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, KA | 2 |
| Suresh Kumar, EV | 1 |
| Wood, SJ | 2 |
| Cromer, JR | 2 |
| Datta, A | 1 |
| David, SA | 5 |
| Wang, H | 2 |
| Wang, T | 2 |
| Hu, X | 1 |
| Deng, C | 1 |
| Jiang, J | 1 |
| Qin, H | 1 |
| Dong, K | 2 |
| Chen, S | 2 |
| Jin, C | 2 |
| Zhao, Q | 2 |
| Du, B | 2 |
| Hu, P | 2 |
| Inamdar, S | 1 |
| Tylek, T | 1 |
| Thumsi, A | 1 |
| Suresh, AP | 1 |
| Jaggarapu, MMCS | 1 |
| Halim, M | 1 |
| Mantri, S | 1 |
| Esrafili, A | 1 |
| Ng, ND | 1 |
| Schmitzer, E | 1 |
| Lintecum, K | 1 |
| de Ávila, C | 1 |
| Fryer, JD | 1 |
| Xu, Y | 1 |
| Spiller, KL | 1 |
| Acharya, AP | 1 |
| Hu, XY | 1 |
| Zhang, W | 1 |
| Wang, D | 1 |
| Sun, Y | 1 |
| Hu, Z | 1 |
| Zang, B | 1 |
| Feng, Y | 1 |
| Zhou, J | 1 |
| Liu, H | 1 |
| Jiang, W | 1 |
| Wang, CY | 1 |
| Yao, X | 1 |
| Zhang, J | 2 |
| Qin, W | 2 |
| Lyu, W | 2 |
| Shen, W | 2 |
| Wang, X | 2 |
| Sun, B | 2 |
| Shrestha, A | 1 |
| Sil, D | 2 |
| Malladi, SS | 1 |
| Warshakoon, HJ | 1 |
| Liu, X | 2 |
| Zheng, X | 2 |
| Long, Y | 2 |
| Cao, H | 2 |
| Wang, N | 2 |
| Lu, Y | 2 |
| Zhao, K | 2 |
| Zhou, H | 2 |
| Zheng, J | 2 |
| Burns, MR | 1 |
| Nguyen, T | 1 |
| Shelton, JL | 1 |
| Wang, L | 1 |
| Cepinskas, G | 1 |
| Sandig, M | 1 |
| Scott, JA | 1 |
| North, ML | 1 |
| Inculet, R | 1 |
| Mehta, S | 1 |
| Noguchi, Y | 1 |
| Meyer, TA | 1 |
| Tiao, G | 1 |
| Ogle, CK | 1 |
| Fischer, JE | 1 |
| Hasselgren, PO | 1 |
| Silverstein, R | 1 |
| Amura, CR | 1 |
| Kielian, T | 1 |
| Morrison, DC | 1 |
2 trials available for spermine and Blood Poisoning
| Article | Year |
|---|---|
Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation.
Topics: Body Weight; Caffeic Acids; Computer Simulation; Dose-Response Relationship, Drug; Humans; Models, B | 2022 |
Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial.
Topics: Caffeic Acids; Double-Blind Method; Humans; Sepsis; Spermine; Treatment Outcome; Vasoconstrictor Age | 2023 |
12 other studies available for spermine and Blood Poisoning
| Article | Year |
|---|---|
Lipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomospermines.
Topics: Amides; Animals; Cell Line; Cell Survival; Escherichia coli; Female; Hemolysis; Humans; In Vitro Tec | 2005 |
Biomaterial mediated simultaneous delivery of spermine and alpha ketoglutarate modulate metabolism and innate immune cell phenotype in sepsis mouse models.
Topics: Animals; Biocompatible Materials; Immunity, Innate; Inflammation; Ketoglutaric Acids; Mice; Phenotyp | 2023 |
[Inhibitory effect of kukoamine B on lung inflammatory responses in mice with sepsis].
Topics: Animals; Caffeic Acids; Disease Models, Animal; Interleukin-1beta; Lung; Male; Mice; Mice, Inbred IC | 2014 |
[Inhibitory effects of Kukoamine B on the inflammatory response of small intestine in lipopolysaccharide-induced septic mice and its potential mechanisms].
Topics: Animals; Caffeic Acids; Cytokines; Disease Models, Animal; Intercellular Adhesion Molecule-1; Interl | 2015 |
Structure-activity relationships of lipopolysaccharide sequestration in N-alkylpolyamines.
Topics: Cell Line; Chemistry, Pharmaceutical; Crystallography, X-Ray; Drug Design; Endotoxins; Humans; Lipop | 2009 |
Development of small-molecule endotoxin sequestering agents.
Topics: Animals; Anti-Inflammatory Agents; Carbohydrate Conformation; Clinical Trials as Topic; Endotoxins; | 2010 |
Dual targets guided screening and isolation of Kukoamine B as a novel natural anti-sepsis agent from traditional Chinese herb Cortex lycii.
Topics: Animals; Biosensing Techniques; Caffeic Acids; Cell Line; CpG Islands; DNA, Bacterial; Drug Discover | 2011 |
Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment.
Topics: Animals; Caffeic Acids; CpG Islands; Cytokines; Disease Models, Animal; DNA-Binding Proteins; Escher | 2011 |
Lysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants.
Topics: Amides; Animals; Anti-Bacterial Agents; Binding, Competitive; Cell Line; Cytokines; Disease Models, | 2005 |
Inducible NO synthase (iNOS) in human neutrophils but not pulmonary microvascular endothelial cells (PMVEC) mediates septic protein leak in vitro.
Topics: Albumins; Cell Survival; Cells, Cultured; Endothelium, Vascular; Free Radical Scavengers; Humans; Lu | 2007 |
Influence of sepsis and endotoxemia on polyamine metabolism in mucosa of small intestine in rats.
Topics: Adenosylmethionine Decarboxylase; Animals; Endotoxins; Intestinal Mucosa; Jejunum; Male; Ornithine D | 1996 |
Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria.
Topics: Animals; Cytokines; Fatty Acids, Monounsaturated; Female; Glycine; Gram-Negative Bacteria; Lipopolys | 1999 |